The APCCC 2026 does not provide an evidence-based guideline; it reports the position of an international panel on decisions where evidence is limited or conflicting. Of 134 questions voted on by 133 experts, consensus was reached on 44 (32.8%) and strong consensus on only 7; the percentages should therefore be read as expert opinion, not as a practice recommendation.
High-risk localized and locally advanced disease
- Most-voted option, without consensus: radiotherapy + long-term ADT ± ARPI was chosen by 62–68%; surgery within a multimodal treatment, by 32–38%. The choice should be individualized according to local extent, comorbidity, patient preference, and availability of high-quality RT.
- cN1 M0: 83% chose RT + long-term ADT + abiraterone for 2 years. It is the most actionable result of the block, although it remains a consensus position and not evidence from a definitive comparative trial.
- Very high risk: 65–71% preferred RT + long-term ADT + abiraterone for 2 years; enzalutamide had minimal uptake.
- Perioperative ARPI before radical prostatectomy: 82% voted against. The vote preceded the publication of PROTEUS; the topic will be revisited at the 2027 localized-prostate-cancer APCCC, so this result should not be turned into a definitive prohibition.
- Baseline testosterone: 79% agreed it should be measured before starting ADT + RT. It is a simple measure, relevant to document castration and to interpret the biochemical response.
- Boost: there was consensus for a focal boost to the dominant lesion (86%) and strong consensus for a boost to positive nodes in cN1 (92%). Evidence for the latter is mainly about feasibility and tolerability, not survival benefit.
Areas without consensus
There was insufficient agreement on:
- Elective pelvic RT in cN0.
- Extended lymph node dissection in patients with PSMA-PET N0.
- Use of genomic classifiers to select ADT duration or to indicate abiraterone.
- Intensification with ARPI in cN1 or in nodes positive only on PSMA-PET.
These are precisely the areas where practice varies widely between centers and where the panel identifies gaps that warrant prospective trials.
After prostatectomy
In pT3N0, ISUP 4–5, and negative margins, there was strong consensus (96%) for surveillance with early salvage RT over adjuvant RT. With positive margins, the same strategy reached consensus (81%).
In practice, this supports close surveillance with early rescue, provided there is a rigorous PSA protocol and the patient has access to and adheres to follow-up. It does not mean "do not treat": it means deferring RT until there is evidence of recurrence, instead of irradiating everyone systematically.
Persistence and biochemical recurrence
| Scenario | Panel result | Practical reading |
|---|---|---|
| Persistent PSA with poor prognosis: short PSADT or ISUP 4–5 | 83%: salvage RT + ADT | RT alone is probably insufficient in high-risk disease. |
| PSA >1 ng/ml, PSADT <9 months or ISUP 4–5 | 75%: irradiate prostate bed + pelvic nodes | The consensus favors widening the field when the risk of nodal disease is high. |
| Recurrence within 3 years, low PSA and long PSADT | 77%: PSMA-PET | A good indication to stage before deciding on local treatment. |
| Recurrence after 3 years, low PSA and long PSADT | 73%: PSMA-PET | It did not reach the threshold; the decision may still be reasonable, but it is less uniform. |
| Early high-risk recurrence, negative PET, and PSA >0.5 ng/ml | 87%: early salvage RT + systemic ADT | A negative PET does not rule out micrometastasis; the panel favors systemic intensification. |
| Oligometastasis on PSMA-PET | 86%: metastasis-directed treatment + systemic therapy | There is agreement on the principle, but not on the optimal regimen or the local modality. |
Messages for the clinic
- Do not read the percentages as an algorithm. The APCCC expresses where an expert panel agrees; the indication still depends on risk, extent, function, comorbidities, and patient preferences.
- Intensification with abiraterone has the strongest support in cN1 M0 compared with other high-risk localized situations, although comparative evidence remains limited.
- Early salvage RT is gaining ground over universal adjuvant RT, even with positive margins, but it requires intensive follow-up.
- PSMA-PET changes staging, not necessarily curative intent. In early recurrence with a negative PET, the panel still favors salvage RT and ADT; in oligometastasis, it favors directed local treatment plus systemic therapy.
- The greatest controversies persist in pelvic RT, extended lymph node dissection, ARPI in PET-positive nodal disease, and the clinical usefulness of genomic classifiers.
Notice
The APCCC 2026 results reflect expert consensus through a modified Delphi process; they do not include a systematic review or meta-analysis and do not replace clinical guidelines or individualized judgment. The article itself states that its purpose is to help navigate controversial areas and to prioritize future research.
Source
Gillessen S, et al. Management of patients with high-risk localised, locally advanced, and biochemically recurrent prostate cancer: report from the 2026 Advanced Prostate Cancer Consensus Conference. European Urology (2026). DOI 10.1016/j.eururo.2026.09.027 · Open-access text